A.M. Adams

604 total citations
18 papers, 455 citations indexed

About

A.M. Adams is a scholar working on Molecular Biology, Genetics and Genetics. According to data from OpenAlex, A.M. Adams has authored 18 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 4 papers in Genetics and 2 papers in Genetics. Recurrent topics in A.M. Adams's work include Muscle Physiology and Disorders (11 papers), RNA Interference and Gene Delivery (7 papers) and RNA Research and Splicing (5 papers). A.M. Adams is often cited by papers focused on Muscle Physiology and Disorders (11 papers), RNA Interference and Gene Delivery (7 papers) and RNA Research and Splicing (5 papers). A.M. Adams collaborates with scholars based in Australia, United States and United Kingdom. A.M. Adams's co-authors include Steve D. Wilton, Sue Fletcher, Francesco Muntoni, George Dickson, Ian R. Graham, Judith C. van Deutekom, Annemieke Aartsma‐Rus, Maria Kinali, Linda Popplewell and Patrick L. Iversen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Molecular Therapy.

In The Last Decade

A.M. Adams

17 papers receiving 448 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A.M. Adams Australia	11	416	95	84	67	30	18	455
Graziella Griffith France	8	482 1.2×	133 1.4×	110 1.3×	50 0.7×	45 1.5×	10	531
C.L. de Winter Netherlands	7	458 1.1×	118 1.2×	99 1.2×	64 1.0×	41 1.4×	7	475
Andy Cheng Australia	4	419 1.0×	139 1.5×	61 0.7×	32 0.5×	27 0.9×	6	489
Fatima Amor France	9	430 1.0×	75 0.8×	60 0.7×	49 0.7×	51 1.7×	10	474
Carsten G. Bönnemann United States	3	304 0.7×	64 0.7×	86 1.0×	93 1.4×	24 0.8×	5	368
T G Sherratt United Kingdom	8	373 0.9×	94 1.0×	78 0.9×	98 1.5×	55 1.8×	10	422
Ludovic Arandel France	9	351 0.8×	96 1.0×	53 0.6×	69 1.0×	62 2.1×	11	393
Penny L Harding Australia	6	513 1.2×	168 1.8×	104 1.2×	64 1.0×	84 2.8×	7	589
Ashlee E. Tyler United States	9	481 1.2×	64 0.7×	86 1.0×	46 0.7×	34 1.1×	9	530
William Lostal France	10	442 1.1×	154 1.6×	42 0.5×	92 1.4×	76 2.5×	15	466

Countries citing papers authored by A.M. Adams

Since Specialization

Citations

This map shows the geographic impact of A.M. Adams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.M. Adams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.M. Adams more than expected).

Fields of papers citing papers by A.M. Adams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.M. Adams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.M. Adams. The network helps show where A.M. Adams may publish in the future.

Co-authorship network of co-authors of A.M. Adams

This figure shows the co-authorship network connecting the top 25 collaborators of A.M. Adams. A scholar is included among the top collaborators of A.M. Adams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.M. Adams. A.M. Adams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Adams, A.M., et al.. (2025). Aqueous extract of Antiaris toxicaria alleviates LPS-induced neuroinflammation by modulating NF-κB signalling. Nutrire. 50(1).

Thompson, Jennifer A., A.M. Adams, Ianthe Pitout, et al.. (2022). Characterising splicing defects of ABCA4 variants within exons 13–50 in patient-derived fibroblasts. Experimental Eye Research. 225. 109276–109276. 5 indexed citations

Flynn, Loren L., Chalermchai Mitrpant, A.M. Adams, et al.. (2021). Targeted SMN Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies. Biomedicines. 9(5). 552–552. 4 indexed citations

Thompson, Jennifer A., Jason Charng, Samuel McLenachan, et al.. (2020). Phenotype–genotype correlations in a pseudodominant Stargardt disease pedigree due to a novel ABCA4 deletion–insertion variant causing a splicing defect. Molecular Genetics & Genomic Medicine. 8(7). e1259–e1259. 11 indexed citations

Li, Dunhui, A.M. Adams, R. Johnsen, Sue Fletcher, & Steve D. Wilton. (2020). Morpholino Oligomer-Induced Dystrophin Isoforms to Map the Functional Domains in the Dystrophin Protein. Molecular Therapy — Nucleic Acids. 22. 263–272. 10 indexed citations

Servián‐Morilla, Emilia, Macarena Cabrera‐Serrano, Eloy Rivas, et al.. (2019). Altered myogenesis and premature senescence underlie human TRIM32-related myopathy. Acta Neuropathologica Communications. 7(1). 30–30. 20 indexed citations

Viola, Helena M., Victoria Johnstone, A.M. Adams, Sue Fletcher, & Livia C. Hool. (2018). A Morpholino Oligomer Therapy Regime That Restores Mitochondrial Function and Prevents mdx Cardiomyopathy. JACC Basic to Translational Science. 3(3). 391–402. 8 indexed citations

Le, Bao T., A.M. Adams, Sue Fletcher, Steve D. Wilton, & Rakesh N. Veedu. (2017). Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro. Molecular Therapy — Nucleic Acids. 9. 155–161. 38 indexed citations

Aung-Htut, May T., Gavin J. Pinniger, A.M. Adams, et al.. (2016). Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies. PLoS ONE. 11(1). e0145620–e0145620. 30 indexed citations

10.

Viola, Helena M., A.M. Adams, Stefan M.K. Davies, et al.. (2014). Impaired functional communication between the L-type calcium channel and mitochondria contributes to metabolic inhibition in the mdx heart. Proceedings of the National Academy of Sciences. 111(28). E2905–14. 43 indexed citations

11.

Luo, Yue‐Bei, Chalermchai Mitrpant, A.M. Adams, et al.. (2014). Antisense Oligonucleotide Induction of Progerin in Human Myogenic Cells. PLoS ONE. 9(6). e98306–e98306. 10 indexed citations

12.

Adams, A.M., et al.. (2011). Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching. BMC Medical Genetics. 12(1). 141–141. 10 indexed citations

13.

Adkin, C., Sue Fletcher, A.M. Adams, et al.. (2011). Multiple exon skipping strategies to by-pass dystrophin mutations. Neuromuscular Disorders. 22(4). 297–305. 16 indexed citations

14.

Fletcher, Sue, et al.. (2010). Dystrophin Isoform Induction In Vivo by Antisense-mediated Alternative Splicing. Molecular Therapy. 18(6). 1218–1223. 20 indexed citations

15.

Mitrpant, Chalermchai, et al.. (2009). Rational Design of Antisense Oligomers to Induce Dystrophin Exon Skipping. Molecular Therapy. 17(8). 1418–1426. 38 indexed citations

16.

Adams, A.M., Graham McClorey, Hong M. Moulton, et al.. (2007). Induced dystrophin exon skipping in human muscle explants. The Journal of Gene Medicine. 9(6). 534–535. 7 indexed citations

17.

Adams, A.M., et al.. (2007). Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Molecular Biology. 8(1). 57–57. 62 indexed citations

18.

Arechavala‐Gomeza, Virginia, Ian R. Graham, Linda Popplewell, et al.. (2007). Comparative Analysis of Antisense Oligonucleotide Sequences for Targeted Skipping of Exon 51 During Dystrophin Pre-mRNA Splicing in Human Muscle. Human Gene Therapy. 18(9). 798–810. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact